Company Description: Neomics is a cell and gene therapy company innovating adoptive cell therapy to cure cancers and mcDNA to usher new era of genetic medicines. NPB5005-V283 Novel effective anti-BCMA CAR T with significant improvement in safety. Starting investigator-initiated trial for multiple myeloma in Ruijin Hospital, China. To compete in a market > $10 B annual sales in the US and China. NPB3200-V308 First-in-class ICS transgene to engineer T cells for persistent efficacy by overcoming immune checkpoint inhibition in treating solid tumors. Developing ICS-engineered TILs as tumor agnostic immunotherapy for NSCLC, melanoma, OC, KC, etc. mcDNA A scalable enzymatic process to manufacture minicircle DNA vectors by removing bacterial backbone and antibiotic resistant gene from parental plasmid DNA. Re-shaping CGT CMC and starting era of DNA medicines.